|Mr. John D. Shulman||Exec. Chairman||N/A||N/A||1963|
|Mr. Fady Boctor M.B.A.||Principal Exec. Officer, Pres & Chief Commercial Officer||519.48k||N/A||1978|
|Mr. Mitchell S. Arnold M.B.A.||VP of Fin. & Chief Accounting Officer||365.92k||N/A||1964|
|Mr. Robert Weinstein||Interim Chief Financial Officer||N/A||N/A||1960|
|Mr. Keith F. Lavan||Advisor||N/A||N/A||1964|
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Petros Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.